Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Instagram
  • Listen to CMAJ podcasts
CMAJ Specialty Spotlight: Cardiology/Nuclear Medicine

Taking PET to heart

Terrence D. Ruddy, Robert A. deKemp and Rob S. Beanlands
CMAJ November 02, 1999 161 (9) 1131;
Terrence D. Ruddy
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert A. deKemp
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rob S. Beanlands
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Responses
  • Metrics
  • PDF
Loading

Technology: Positron emission tomography (PET)

Use: PET is an advanced imaging technique that allows non-invasive measurement of absolute concentrations of positron-emitting radiotracers, with high spatial and temporal resolution. Various short-lived isotopes are used to label naturally occurring compounds in the body and other analogues. PET is a tremendous research tool for the evaluation of myocardial perfusion, metabolism, receptors and autonomic innervation.

With perfusion tracers such as rubidium-82 or nitrogen-13 ammonia, PET has the highest diagnostic accuracy among the noninvasive tests for the detection of coronary artery disease (CAD)1 and can be used to evaluate serial changes in perfusion reserve. PET imaging using fluorine-18-labelled fluorodeoxyglucose ([18F]FDG) can identify viable ischemic myocardium in patients with CAD and impaired left ventricular function (Figure). The presence of significant [18F]FDG in areas of reduced perfusion indicates viable, "hibernating" myocardium and identifies patients who will benefit from revascularization.2

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure. PET image of left ventricular myocardium (left lateral view), showing myocardial perfusion using 82Rb (left) and glucose metabolism using [18F]FDG (right). Lateral and inferior walls have reduced perfusion (blue) and normal metabolism (red), indicating viable ischemic myocardium that would benefit from revascularization.

History: The original positron scanner, used for imaging brain tumours, was first described in 1953 by Brownell and Sweet.3 With the introduction of medical cyclotrons in the 1970s, PET developed as a powerful but expensive research tool. Over the past decade technology has improved markedly and become much less expensive with the introduction of fully 3-dimensional partial-ring cameras, high-speed computers and automated approaches to kinetic data analysis. The cardiac PET centre at the University of Ottawa Heart Institute, established in 1995, was the first PET centre in Canada dedicated to cardiac imaging. The initial PET [18F]FDG studies demonstrated that viability studies could be carried out without an onsite cyclotron.4 PET perfusion imaging using generator-produced 82Rb and a fully 3-dimensional partial-ring camera was first demonstrated at our institution5 and has been used routinely there since 1997.

Promise: In clinical practice cardiac PET is used to diagnose and evaluate CAD, particularly in patients with equivocal or, possibly, false-positive results from conventional stress echocardiography or from stress thallium-201, sestamibi or tetrofosmin myocardial perfusion imaging. The greater specificity of PET perfusion imaging can reduce costs by decreasing the need for more expensive and higher-risk evaluation with coronary angiography. Similarly, PET viability imaging can facilitate the decision for revascularization, medical therapy or transplantation in patients with left ventricular dysfunction, and it may result in better patient management and optimal resource utilization.

Problems: High capital and operating costs of a PET centre have delayed widespread clinical implementation and have limited access for routine clinical care. Recent advances in technology have reduced costs, however. As well, cost-benefit analyses have shown significant savings with PET imaging as a decision-making tool in the management of patients with chest pain and possible CAD and in patients with severe left ventricular dysfunction. Results from current studies will define the appropriate patient groups for PET evaluation and the most cost-effective management options.

Prospects: Clinical use of cardiac PET will continue to increase. PET perfusion imaging has the highest diagnostic accuracy for CAD, and viability studies in the growing population of patients with congestive heart failure can assist in choosing from among the increasing number of treatment options. Newer applications for imaging cardiac innervation may be helpful in treating arrhythmia. Future research and development of radiopharmaceuticals, receptor ligands and other compounds for PET imaging may also help advance our understanding of cardiovascular disease and its treatment.

Competing interests: None declared.

References

  1. 1.↵
    Demer LL, Gould KL, Goldstein RA, Kirkeeide RL, Mullani NA, Smalling RW, et al. Assessment of coronary artery disease severity by positron emission tomography: comparison with quantitative arteriography in 193 patients. Circulation 1989;79:825-35.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    Beanlands RS, Hendry PJ, Masters RG, deKemp RA, Woodend K, Ruddy TD. Delay in revascularization is associated with increased mortality rate in patients with severe left ventricular dysfunction and viable myocardium on fluorine 18-fluorodeoxyglucose positron emission tomography imaging. Circulation 1998;98(Suppl 19):II51-6.
  3. 3.↵
    Brownell GL, Sweet WH. Localization of brain tumors with positron emitters. Nucleonics 1953;11:40-5.
    OpenUrl
  4. 4.↵
    Beanlands RSB, deKemp RA, Culbert P, Smith S, Hendry P, Davies RA, et al. Myocardial glucose metabolism in severe ischemic left ventricular dysfunction [abstract]. Can J Cardiol 1995;11:104E.
    OpenUrl
  5. 5.↵
    Ruddy TD, deKemp RA, Dalipaj MM, Aung MT, Vincent JS, Beanlands RS. Quantification of myocardial perfusion with Rb-82 and PET in myocardial infarction [abstract]. Can J Cardiol 1996;12:155E.
    OpenUrlPubMed
PreviousNext
Back to top

In this issue

CMAJ
Vol. 161, Issue 9
2 Nov 1999
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Taking PET to heart
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Taking PET to heart
Terrence D. Ruddy, Robert A. deKemp, Rob S. Beanlands
CMAJ Nov 1999, 161 (9) 1131;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Taking PET to heart
Terrence D. Ruddy, Robert A. deKemp, Rob S. Beanlands
CMAJ Nov 1999, 161 (9) 1131;
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • References
  • Figures & Tables
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

Similar Articles

Collections

  • Topics
    • Cardiology: ischemic heart disease
    • Imaging

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: [email protected]

CMA Civility, Accessibility, Privacy

 

Powered by HighWire